RUBY Rubius Therapeutics

Rubius Therapeutics to Announce Third Quarter 2021 Financial Results

Rubius Therapeutics to Announce Third Quarter 2021 Financial Results

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report third quarter financial results on Monday, November 8, 2021, after market close.

The company will not be hosting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was named among the 2020 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2021 Best Places to Work in Rhode Island by Providence Business News. For more information, visit , follow us on or or like us on .

Contacts:

Elhan Webb, CFA

Vice President, Investor Relations





Media: 

Marissa Hanify

Director, Corporate Communications

Dan Budwick

1AB

+1 (973) 271-6085



EN
28/10/2021

Underlying

RUBYRubius Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Rubius Therapeutics

 PRESS RELEASE
Free
RUBY Rubius Therapeu...

Rubius Therapeutics Announces Process to Explore Strategic Alternative...

Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives...

November 2, 2022 1 EN
 PRESS RELEASE
Free
RUBY Rubius Therapeu...

Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Co...

Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT. A live audio webcast will...

September 19, 2022 1 EN
 PRESS RELEASE
Free
RUBY Rubius Therapeu...

Rubius Therapeutics Announces Strategic Update

Rubius Therapeutics Announces Strategic Update Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid Tumors Investor Teleconference and Webcast Scheduled Today at 7:30 a.m. EDT CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular med...

September 13, 2022 1 EN
 PRESS RELEASE
Free
RUBY Rubius Therapeu...

Rubius Therapeutics to Provide Strategic Update

Rubius Therapeutics to Provide Strategic Update Investor Teleconference and Webcast Scheduled Tomorrow, September 13, 2022, at 7:30 a.m. EDT CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the Company plans to provide a strategic update and host an investor teleconference and webcast on Tuesday,...

September 12, 2022 1 EN
 PRESS RELEASE
Free
RUBY Rubius Therapeu...

Rubius Therapeutics Reports Second Quarter 2022 Financial Results and ...

Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial Clinical Results Expected in 2H’22 from Phase 1 Arm of RTX-240 + Pembrolizumab in Advanced Solid Tumors and Expansion Cohorts in Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Dose Escalation Continues in Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date; Initial ...

August 9, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch